Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Viruses with RNA Genomes01:29

Viruses with RNA Genomes

1.2K
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
1.2K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

57
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
57

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recombinant polyclonal antibody GIGA-2339 potently and pan-genotypically neutralizes hepatitis B virus.

Antiviral research·2026
Same author

B-BEST: Profiling the intrahepatic HBV reservoir at single-cell resolution.

Hepatology (Baltimore, Md.)·2026
Same author

HDV sensing drives USP18-mediated refractoriness to IFN-α response, sparing IFN-β/λ in hepatocytes.

Antiviral research·2026
Same author

Research without borders: advancing equitable global partnerships to accelerate HBV elimination efforts.

Nature reviews. Gastroenterology & hepatology·2026
Same author

Hepatitis D Virus: Enigmas and Gaps of Knowledge.

Viruses·2026
Same author

Adenine Base Editing Potently Suppresses Hepatitis B Surface Antigen Expression and Inhibits Hepatitis D Virus Release.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Mar 9, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.7K

Novel targets for hepatitis B virus therapy.

Barbara Testoni1,2,3, David Durantel1,2,3, Fabien Zoulim1,2,3,4

  • 1INSERM, U1052, Lyon, France.

Liver International : Official Journal of the International Association for the Study of the Liver
|January 5, 2017
PubMed
Summary

Current hepatitis B treatments suppress viral load but rarely eliminate infection. New strategies targeting viral replication and immune response are needed for a complete cure, requiring combined therapies and defined treatment correlates.

Keywords:
hepatitis B virusimmunotherapyviral targets

More Related Videos

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
05:55

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

7.2K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.1K

Related Experiment Videos

Last Updated: Mar 9, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.7K
Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
05:55

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

7.2K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.1K

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Chronic hepatitis B (CHB) treatments like pegylated interferon-alpha (pegIFN-α) and nucleos(t)ide analogues (NAs) suppress viral load but achieve limited HBsAg loss.
  • Long-term NA therapy does not eliminate the persistent hepatitis B virus (HBV) minichromosome, leaving risks of cirrhosis and hepatocellular carcinoma.
  • Advances in HBV infection models fuel research into viral life cycle and host interactions for novel therapeutic targets.

Purpose of the Study:

  • To explore new therapeutic strategies for achieving a functional cure of chronic hepatitis B.
  • To identify novel drug targets by investigating HBV replication and virus-host interactions.
  • To evaluate the potential of combining direct antiviral therapies with immune-modulating approaches.

Main Methods:

  • Investigating direct inhibition of HBV replication targeting entry, cccDNA, transcription, capsid assembly, and secretion.
  • Exploring host immune system manipulation, including boosting innate responses and restoring adaptive immunity.
  • Developing strategies such as engineered HBV-specific T cells, negative regulator inhibitors, and therapeutic vaccines.

Main Results:

  • Multiple therapeutic strategies are under investigation for HBV cure.
  • Directly targeting viral replication and enhancing host immunity are key approaches.
  • Combination therapies are essential for achieving a cure.

Conclusions:

  • Achieving a cure for chronic hepatitis B requires a multi-pronged therapeutic approach.
  • Combining direct-acting antivirals with immunotherapies shows promise.
  • Defining clinical, virological, and immunological correlates is crucial for managing treatment and assessing cure.